Glaukos Announces FDA Approval of Epioxa™
Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, IncisionFree, Topical Drug Therapy for Keratoconus Epioxa Represents a Novel, Groundbreaking Therapy for Patients Afflicted by This Sight-Threatening Rare Disease Epioxa Expected to Be Commercially Available in Q1 2026 Aliso Viejo, CA – October 20, 2025 – Glaukos Corporation (NYSE: GKOS), an…
View details